Lyme vaccines, antibody shots, and pills for ticks are coming

Key Points:

• Lyme disease affects over 470,000 Americans annually, with Massachusetts reporting over 1,800 cases this year; up to 20% of treated patients experience long-term symptoms known as post-treatment Lyme disease syndrome.
• Pfizer and Valneva have completed a late-stage trial of a new Lyme vaccine that reduces infection risk by over 70%, working by delivering antibodies into ticks through vaccinated individuals' blood; this could become the first US-approved Lyme vaccine in over two decades.
• The new vaccine resembles the 1998 Lymerix vaccine, which was withdrawn due to poor sales despite proven safety and efficacy; growing awareness of tick-borne diseases may lead to higher acceptance of Pfizer’s vaccine.
• Alternative prevention methods in development include monoclonal antibody shots that provide direct protection and oral medications like Tarsus Pharmaceuticals' pill that kills ticks after attachment, potentially reducing multiple tick-borne illnesses.
• Experts caution that vaccines and antibody treatments may require multiple doses and boosters, may not protect against all tick-borne diseases, and could face challenges in public adoption and cost, but represent promising advances in Lyme disease prevention.